IL6 and cancer: This activation drives the expression of inflammatory ligands, growth factors, chemokines, extracellular vesicles, metabolite, EV-related molecules and so on, such as interleukin-6 (IL-6) [55], which further contribute to the EMT in cancer cells, enhancing tumor invasiveness, metastasis [56], therapy resistance [57], immune evasion [58], and relapse [59].